Tricida

About Tricida

Tricida, Inc. is a pharmaceutical company that focuses on developing and commercializing therapeutics, specifically targeting kidney-related diseases. Founded in August 2013, the company is led by a seasoned management team with extensive experience in the field. Tricida's core product is veverimer, also known as TRC101, a non-absorbed, orally administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition often caused by CKD, which can accelerate the progression of the disease, increase the risk of muscle wasting, and cause bone loss.

Tricida operates in the pharmaceutical market, primarily serving patients with chronic kidney disease. The company's business model revolves around the development and commercialization of its drug candidate, veverimer. Revenue is generated through the sale of this therapeutic once it receives regulatory approval and enters the market.

Tricida's approach involves extensive research and development, clinical trials, and regulatory submissions to ensure the safety and efficacy of veverimer. The company aims to address a significant unmet medical need, providing a solution for patients suffering from metabolic acidosis due to CKD.